전이성 삼중음성 유방암에서 Sacituzumab Govitecan

Bardia 등(수요일,)이 이 질문을 연구했다.

www.synapsesocial.com/papers/69cac1a5c138251ffc5f8144 — DOI: https://doi.org/10.1056/nejmoa2028485

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer· 2019 · 838 citations
2. The National Comprehensive Cancer Network· 1998 · 16,869 citations
3. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).· 2001 · 752 citations
4. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)· 2016 · 2,062 citations
5. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial· 2012 · 127 citations